Ann Pediatr Endocrinol Metab.  2021 Sep;26(3):205-209. 10.6065/apem.2040206.103.

Immobilization-induced symptomatic hypercalcemia treated with zoledronate in a child with a left ventricular assist device

• Gün E
• Kendirli T
• Botan E
• Uçar T
• Aycan Z
• Akar AR

• KMID: 2520514
• DOI: http://doi.org/10.6065/apem.2040206.103

Abstract

Differential diagnosis of hypercalcemia in children includes confirmation of hyperthyroidism, infection, inflammatory processes, and malignant tumors. Immobilization-induced hypercalcemia is rare in healthy individuals, although it can occur in adolescent males, especially after fracture. Immobility can cause increased skeletal calcium release and hypercalcemia, and this condition is also known as resorptive hypercalcemia. We present a case of a 10-year-old adolescent girl with advanced heart failure who underwent implantation with a HeartMate 3 left ventricular assist device. She had symptoms of abdominal pain, vomiting, and constipation on the fifth month of hospitalization. She subsequently developed immobilization-induced symptomatic hypercalcemia (serum calcium, 12.1 mg/dL; corrected calcium 12.8 mg/dL; parathormone, 1.9 pg/mL; calcium/creatinine ratio in spot urine, 1.21). However, hypercalcemia is uncommon in children with advanced heart failure. Bisphosphonate therapy was initiated because our patient did not respond to hydration and furosemide treatment, and she had persistent abdominal pain, vomiting, and constipation. The patient's complaints were resolved on the second day after administrating bisphosphonate, and hypercalcemia did not recur.

Keyword

Hypercalcemia; Child; Mechanical circulatory support; Left ventricular assist device

Reference

References

1. Henry RK, Gafni RI. Hypercalcemia due to Milk-Alkali Syndrome and fracture-induced immobilization in an adolescent boy with hypoparathyroidism. Horm Res Paediatr. 2016; 86:201–5.

2. Uehara A, Yazawa M, Kawata A, Hachisuka R, Shibagaki Y. Denosumab for treatment of immobilization-related hypercalcemia in a patient with end-stage renal disease. CEN Case Rep. 2017; 6:111–4.

3. Yusuf MB, Akinyoola AL, Orimolade AE, Idowu AA, Badmus TA, Adeyemi TO. Determinants of hypercalcemia and hypercalciuria in immobilized trauma patients. Bonekey Rep. 2015; 4:709.

4. Cano-Torres EA, Gonzalez-Cantu A, Hinojosa-Garza G, Castilleja-Leal F. Immobilization induced hypercalcemia. Clin Cases Miner Bone Metab. 2016; 13:46–7.

5. Bernhardt AM, Schloglhofer T, Lauenroth V, Mueller F, Mueller M, Schoede A, et al. Prevention and early treatment of driveline infections in ventricular assist device patients - The DESTINE staging proposal and the first standard of care protocol. J Crit Care. 2019; 56:106–12.

6. Barac YD, Wojnarski CM, Junpaparp P, Jawitz OK, Billard H, Daneshmand MA, et al. Early outcomes with durable left ventricular assist device replacement using the HeartMate 3. J Thorac Cardiovasc Surg. 2020; 160:132–9.e1.

7. Lui C, Suarez-Pierre A, Zhou X, Crawford TC, Fraser CD, Giuliano K, et al. Effects of systemic and device-related complications in patients bridged to transplantation with left ventricular assist devices. J Surg Res. 2020; 246:207–12.

8. Vyas N, Kaminski B, MacLeish S. A rare case report of immobility-induced hypercalcemia in an infant. Pediatrics. 2016; 137:e20150879.

9. Linstow MV, Biering-Sorensen F. Immobilisation-induced hypercalcemia following spinal cord injury affecting the kidney function in two young native Greenlanders. Spinal Cord Ser Cases. 2017; 3:17010.

10. Albright F, Burnett CH, Cope O, Parson W. Acute atrophy of bone (osteoporosis) simulating hyperparathyroidism. J Clin Endocrinol Metab. 1941; 1:711–6.

11. Patel N, Sharma A, Dalia T, Rali A, Earnest M, Tadros P, et al. Vascular complications associated with percutaneous left ventricular assist device placement: a 10-year US perspective. Catheter Cardiovasc Interv. 2020; 95:309–16.

12. Yamada S, Arase H, Tachibana S, Tomita K, Eriguchi M, Fujisaki K, et al. Immobilization-induced severe hypercalcaemia successfully treated with reduced dose of zoledronate in a maintenance haemodialysis patient. Nephrology (Carlton). 2018; 23:963–4.